{"analyses":[{"ciLowerLimit":"88.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"100.00","groupDescription":"A 95% CI was calculated on the percentage of participants with a Response or Stable Disease using the exact (Clopper-Pearson) method.","groupIds":["OG000"],"nonInferiorityType":"OTHER","paramType":"Percentage of Participants","paramValue":"100.00","statisticalMethod":"Clopper-Pearson"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Stable Disease (SD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Disease control rate is defined as the percentage of subjects who have a best overall response of Complete response (CR) or Partial response (PR) or Stable disease (SD) by RECIST 1.1 as assessed by the Investigator. For participants with a best overall response of SD, a RECIST assessment of SD must have been observed at least 6 weeks minus 1 week (at least 35 study days) following the first dose.\n\nPer the protocol, the safety run-in treatment arms were combined and analyzed regardless of chemotherapy received for consistency with the randomized component.","groups":[{"description":"Includes all participants in both Safety Run-In treatment arms: AZD9291 + Carboplatin + Pemetrexed and AZD9291 + Cisplatin + Pemetrexed","id":"OG000","title":"Overall Safety Run-In Participants"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set, includes all participants in the Safety Run-In Treatment Arms who received at least 1 dose of study treatment (osimertinib, cisplatin, carboplatin, or pemetrexed).","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Disease Control Rate (DCR) by Investigator (Safety Run-In Treatment Arms Only)","type":"SECONDARY","unitOfMeasure":"Participants"}